Novavax (NASDAQ:NVAX) Issues Earnings Results

Novavax (NASDAQ:NVAX) posted its earnings results on Thursday. The biopharmaceutical company reported ($0.51) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.24, RTT News reports. The company had revenue of $88.31 million for the quarter, compared to the consensus estimate of $85.48 million. During the same period in the previous year, the firm posted ($1.44) EPS.

Novavax Trading Down 3.6 %

NASDAQ NVAX opened at $7.06 on Friday. The firm has a market capitalization of $1.13 billion, a PE ratio of -3.12, a price-to-earnings-growth ratio of 2.85 and a beta of 2.14. The business’s 50-day moving average price is $8.52 and its two-hundred day moving average price is $10.00. Novavax has a 12 month low of $3.81 and a 12 month high of $23.86.

Insider Transactions at Novavax

In other news, Director Rachel K. King sold 4,150 shares of the stock in a transaction on Friday, December 13th. The shares were sold at an average price of $9.02, for a total transaction of $37,433.00. Following the completion of the sale, the director now directly owns 14,770 shares in the company, valued at $133,225.40. This represents a 21.93 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director James F. Young sold 4,600 shares of the business’s stock in a transaction on Tuesday, December 24th. The shares were sold at an average price of $8.48, for a total transaction of $39,008.00. Following the completion of the transaction, the director now owns 57,160 shares in the company, valued at approximately $484,716.80. The trade was a 7.45 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 14,150 shares of company stock worth $119,641 over the last ninety days. 1.00% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on NVAX. HC Wainwright restated a “buy” rating and set a $19.00 price objective on shares of Novavax in a research report on Tuesday, December 10th. BTIG Research started coverage on Novavax in a report on Friday. They set a “buy” rating and a $19.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $18.00.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.